Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin
Autore:
Turban, S; Fuentes, F; Ferlic, L; Brugada, R; Gotto, AM; Ballantyne, CM; Marian, AJ;
Indirizzi:
Baylor Coll Med, Cardiol Sect, Dept Med, Houston, TX 77030 USA Baylor CollMed Houston TX USA 77030 ect, Dept Med, Houston, TX 77030 USA Baylor Coll Med, Sect Atherosclerosis, Dept Med, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 sis, Dept Med, Houston, TX 77030 USA Cornell Univ, Weill Med Coll, New York, NY 10021 USA Cornell Univ New York NY USA 10021 Weill Med Coll, New York, NY 10021 USA
Titolo Testata:
ATHEROSCLEROSIS
fascicolo: 3, volume: 154, anno: 2001,
pagine: 633 - 640
SICI:
0021-9150(20010215)154:3<633:APSOPG>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY-LIPOPROTEIN; ARTERY DISEASE; HEART-DISEASE; OXIDATIVE MODIFICATION; SERUM PARAOXONASE; GLN-ARG192 POLYMORPHISM; MYOCARDIAL-INFARCTION; MOLECULAR-BASIS; INCREASED RISK; HUMPONA GENE;
Keywords:
paraoxonase; genetics; coronary artery disease; polymorphism;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Marian, AJ Baylor Coll Med, Cardiol Sect, Dept Med, 1 Baylor Plaza, 543E, Houston, TX77030 USA Baylor Coll Med 1 Baylor Plaza, 543E Houston TX USA 77030 0 USA
Citazione:
S. Turban et al., "A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin", ATHEROSCLER, 154(3), 2001, pp. 633-640

Abstract

Human serum paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated enzyme that is responsible for the protective effect of HDL against oxidation of low-density lipoprotein (LDL). PON1 has a Glu to Arg polymorphismat codon 192 (CGA --> CAA) which is designated R/Q192. The R/Q192 polymorphism has been associated with coronary artery disease (CAD) in several, butnot all, case-control studies. We prospectively studied the association ofthe Q/R192 genotypes with the severity, progression and regression of CAD,plasma lipid levels, clinical events and response to treatment with fluvastatin in a well-characterized cohort. Genotypes were determined by polymerase chain reaction (PCR) and restriction mapping with Alw1 enzyme in 356 subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS). Fastingplasma lipids were measured and quantitative coronary angiograms were obtained at baseline and 7.5 years following randomization to fluvastatin or placebo. A total of 177 (50%), 142 (40%) and 37 (10%) subjects had Q/Q, Q/R and R/R genotypes, respectively. Baseline and final plasma levels of HDL, LDL, triglyceride and other lipoproteins, lesion-specific minimum lumen diameters (MLD), mean MLD, number of coronary lesions and total occlusions at baseline and follow-up and clinical event rates were not significantly different among the genotypes. There was no genotype-treatment interaction with respect to plasma lipid levels and angiographic indices of CAD. The Q/R 192 variants of PON1 are not associated with severity, progression or regression of coronary atherosclerosis, plasma lipid levels, clinical events. or response to treatment with fluvastatin. Thus, the Q/R192 polymorphism is not amajor risk factor in susceptibility to CAD in the LCAS population. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 06:54:09